$PDLI News

Last published 1y ago

1y agoAVID FOR HSON IGT+14Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual MeetingBusiness WireIntends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or
2y agoPHGE OWW PDLIBiomX Announces the Appointment of Susan Blum to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target
4y agoFACT FPRX PDLIApexigen Announces Appointment of Francis Sarena as Chief Operating OfficerGlobeNewswireSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sa
5y agoPDLIPDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with WellstatPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps...
5y agoALPN SGEN XOMA PDLIAlpine Immune Sciences Appoints Natasha Hernday to Board of DirectorsBusiness WireSEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy.
5y agoPDLIPDL Announces Timeline for Voluntarily Delisting from NasdaqPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent ...
6y agoPDLIPDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of DissolutionPR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and...
6y agoLNSR PDLILENSAR Reports Third Quarter 2020 Financial Results and Provides Business UpdateBusiness WireORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the third quarter ended September 30, 2020 and provided an update on key strategic and operational initiatives. The distribution of LENSAR common stock to st ...
6y agoPDLIPDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business UpdatePR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results ...
6y agoPDLIPDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020PR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period...
6y agoLNSR PDLILENSAR, Inc. Begins Trading on NASDAQBusiness WireORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the completion of its spin-off from PDL BioPharma, Inc. (NASDAQ: PDLI) (“PDL”). Beginning today, LENSAR shares will commence “regular-way” trading on the NASDAQ Stock Market.
6y agoPDLIPDL BioPharma Completes Spin-Off of LENSARPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its...
6y agoPDLIPDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020PR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that its Board of Directors has approved the separation of LENSAR, Inc....
6y agoPDLIPDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley CapitalPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and...
6y agoPDLI SWKHPDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings CorporationPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty ...
6y agoPDLIPDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024PR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021...
6y agoPDLIPDL BioPharma Announces Filing of a Form 10 Registration Statement with the Securities and Exchange Commission for a Potential Spin-off of LENSAR to PDL's StockholdersPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that its majority owned medical device subsidiary, LENSAR, Inc. ("LENSAR"), has ...
6y agoPDLIPDL BioPharma Enters Into Settlement Agreement with WellstatPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a settlement agreement (the "Settlement Agreement") with...
6y agoPDLIPDL BioPharma Reports 2020 Second Quarter Financial ResultsPR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2020 and provides...
6y agoPDLIPDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020PR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period...
6y agoPDLIPDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley CapitalPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding...
6y agoPDLI EVFMPDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL StockholdersPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the...
6y agoPDLI EVFMPDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL StockholdersPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all...
6y agoPDLIPDL BioPharma Reports 2020 First Quarter Financial ResultsPR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three months ended March 31, 2020 and provides a...
6y agoPDLI EVFMPDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL StockholdersPR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that the Company's Board of Directors has approved a distribution of all of the ...
6y agoPDLIPDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020PR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period...
6y agoPDLIPDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020PR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) provides an update on its strategic plans and reports financial results for the three and ...
6y agoPDLIPDL BioPharma Announces Appointment of Edward A. Imbrogno as Vice President and Chief Financial OfficerPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the appointment of Edward A. Imbrogno as the Company's Vice President and ...
6y agoPDLIPDL BioPharma Enters into Cooperation Agreement with Engine CapitalPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital...
6y agoPDLIPDL BioPharma to Participate in the Cowen and Company 40th Annual Health Care ConferencePR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, will...
6y agoPDLIPDL BioPharma Announces Upcoming Changes to its Board of DirectorsPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced upcoming changes to the Company's Board of Directors. Elizabeth...
6y agoPDLIPDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 MillionPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that its Board of Directors has authorized a $75 million increase to the...
6y agoPDLIPDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024PR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange...
6y agoPDLIPDL BioPharma Announces Completion of Strategic Review ProcessPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that it has completed the strategic review process that it initiated in...
6y agoPDLI EVFMPDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®PR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM) on its recent...
6y agoPDLIPDL BioPharma Reaffirms Commitment To Shareholder Value CreationPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine")...
6y agoPDLIEngine Capital Releases Presentation To Board Of PDL BioPharmaPR NewswireEngine Capital LP (together with its affiliates, "Engine"), a significant shareholder of PDL BioPharma, Inc. ("PDLI" or the "Company") (Nasdaq:...
7y agoPDLIPDL BioPharma Reports 2019 Third Quarter Financial ResultsPR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2019: Third...
7y agoPDLIPDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019PR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the...
7y agoPDLIPDL BioPharma Responds to Letter from Engine CapitalPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick, Ph.D., Chairman of the Board of Directors of PDL...
7y agoPDLIEngine Capital Issues Open Letter to Board of PDL BioPharmaPR NewswireEngine Capital LP (together with its affiliates, "Engine"), a significant shareholder of PDL BioPharma, Inc. (the "Company") (NASDAQ:PDLI), with...
7y agoPDLIPDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare ConferencePR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, will...
7y agoPDLIPDL BioPharma Announces Private Exchange of Approximately $86.1 Million of Convertible Notes Due 2024PR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated transactions to...
7y agoPDLIPDL BioPharma Announces Favorable Decision in Wellstat Diagnostics LitigationPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that the Supreme Court of New York, County of New York, Commercial Division,...
7y agoPDLIPDL BioPharma's (PDLI) CEO Dominique Monnet on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
7y agoPDLIPDL BioPharma Reports 2019 Second Quarter Financial ResultsPR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2019: Second...
7y agoPDLIPDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019PR NewswirePDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its second quarter 2019 financial results for the...
7y agoPDLIPDL BioPharma Announces Departure of CFOPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia, who will be...
7y agoPDLINatasha A. Hernday Elected to PDL BioPharma's Board of DirectorsPR NewswirePDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019, the...
7y agoPDLIPDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q1 2019 Results - Earnings Call TranscriptEarnings Call Transcripts